Pioglitazone News and Research

RSS

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.

22 Feb 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

Pioglitazone can prevent long term effects of maternal obesity on offspring

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication Pioglitazone can prevent the long term effects of maternal obesity on offspring.

13 Feb 2012

Length of residence in the U.S. increases risk of PTB among Hispanic women

The longer a Hispanic woman lives in the United States, the higher her risk of preterm birth (PTB), with nearly half of PTBs among Hispanic women occurring in those who were born in the U.S.

13 Feb 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

Mylan confirms Actoplus Met XR patent challenge

Mylan Inc. today confirmed that the company has been sued by Takeda Pharmaceutical Company, Watson Pharmaceuticals and Andrx Labs in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Pioglitazone Hydrochloride and Extended-release Metformin Hydrochloride tablets, 15 mg/1000 mg and 30 mg/1000 mg.

9 Jan 2012

Positive results from Aestus' ATx08-001 Phase II study on post-herpetic neuralgia

Aestus Therapeutics, Inc. today reported positive results from a Phase II clinical study evaluating the efficacy of its novel neuropathic pain therapeutic, ATx08-001, in the treatment of post-herpetic neuralgia.

14 Dec 2011

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet.

24 Nov 2011

FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed.

18 Nov 2011

Glitazone treatment does not cause side effects in patients with metastatic thyroid cancer

Repeated radio-ablation therapy with iodine-131 to treat metastatic thyroid cancer can be less effective than the initial round of treatment due to de-differentiation of the cancer cells as the disease progresses, making them less sensitive to I-131.

29 Oct 2011

Increasing levels of 'good' cholesterol reduces risk for heart attack and stroke among diabetics

Increasing levels of high-density lipoproteins, better known as HDL or "good" cholesterol, reduced the risk for heart attack and stroke among patients with diabetes. That's according to a new study appearing online today in The American Journal of Cardiology.

7 Oct 2011

Linagliptin demonstrates durable reductions in blood glucose for T2D adults

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 102 week Phase III study for linagliptin, which show meaningful and durable reductions in blood glucose for adults with type 2 diabetes.

16 Sep 2011

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free - at least in mice - of dangerous side effects plaguing some current diabetes medications.

9 Sep 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

$Inhaled corticosteroids linked to increased risk of fractures in patients with COPD$

Inhaled corticosteroids linked to increased risk of fractures in patients with COPD

Patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids to improve breathing for more than six months have a 27 percent increased risk of bone fractures, new Johns Hopkins-led research suggests.

24 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Medical societies urge diabetes patients to remain on their prescribed medications

Diabetes leaders today are responding to the announcement made by the U.S. Food and Drug Administration (FDA) yesterday that the use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.

17 Jun 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011